PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
Switching from finasteride to dutasteride caused significant shedding but minimal side effects. The user plans to continue dutasteride for 12 months despite concerns about hair density.
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
A user has been using oral minoxidil for 4 months and oral finasteride for over a year without side effects. Responses praise the user's hair regrowth and healthy appearance.
1533 citations
,
October 2008 in “Endocrine reviews”
This research highlights that engineered mice lacking the vitamin D receptor show multiple health issues similar to human vitamin D deficiency, underscoring the widespread impacts of the vitamin D endocrine system.
This study reports that miR-302 promotes pluripotency by inhibiting NR2F2 and indirectly regulating OCT4 in stem cells, enhancing reprogramming efficiency when added to traditional factors.
85 citations
,
July 2012 in “Cold Spring Harbor perspectives in biology”
This article discusses the roles of epidermal stem cells in maintaining skin homeostasis and highlights how deregulation in signaling pathways may lead to cancer, but it reports no new experimental results.